Genzyme Corporation Release: Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif?? in Phase lll Trial

CAMBRIDGE, Mass. April 24, 2012 Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), reports today additional data from the Phase lll CARE-MS ll trial.
Read the full story: BioSpace.com Featured News